PKD2/PRKD2 (G848E)

PRKD2 · Variant type: point · HGVS: p.G848E

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Sunitinib	80.3%	19.7%	91.73
2	Neratinib	68.4%	31.6%	93.18
3	Abemaciclib	60.2%	39.8%	91.48
4	Palbociclib	49.8%	50.2%	98.75
5	Ripretinib	47.5%	52.5%	92.95
6	Darovasertib	41.7%	58.3%	96.99
7	Gilteritinib	35.0%	65.0%	88.97
8	Capivasertib	31.5%	68.5%	96.48
9	Pacritinib	31.1%	68.9%	88.64
10	Canertinib	25.5%	74.5%	96.49
11	Defactinib	23.1%	76.9%	92.68
12	Rabusertib	15.2%	84.8%	98.74
13	Tivozanib	13.8%	86.2%	92.42
14	Quizartinib	12.5%	87.5%	99.50
15	Erlotinib	10.3%	89.7%	99.75
16	Vandetanib	9.4%	90.6%	95.74
17	Selumetinib	9.2%	90.8%	100.00
18	Cobimetinib	8.8%	91.2%	100.00
19	Zanubrutinib	8.5%	91.5%	98.24
20	Lazertinib	8.4%	91.6%	97.47
21	Upadacitinib	8.2%	91.8%	97.98
22	Apatinib	7.8%	92.2%	97.73
23	Alpelisib	6.6%	93.4%	97.22
24	Gedatolisib	6.5%	93.5%	99.75
25	Entrectinib	6.4%	93.6%	93.69

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Sunitinib	80.3%	—	—
Neratinib	68.4%	—	—
Abemaciclib	60.2%	—	—
Palbociclib	49.8%	—	—
Ripretinib	47.5%	—	—
Darovasertib	41.7%	—	—
Gilteritinib	35.0%	—	—
Capivasertib	31.5%	—	—
Pacritinib	31.1%	—	—
Canertinib	25.5%	—	—
Defactinib	23.1%	—	—
Rabusertib	15.2%	—	—
Tivozanib	13.8%	—	—
Quizartinib	12.5%	—	—
Erlotinib	10.3%	—	—
Vandetanib	9.4%	—	—
Selumetinib	9.2%	—	—
Cobimetinib	8.8%	—	—
Zanubrutinib	8.5%	—	—
Lazertinib	8.4%	—	—
Upadacitinib	8.2%	—	—
Apatinib	7.8%	—	—
Alpelisib	6.6%	—	—
Gedatolisib	6.5%	—	—
Entrectinib	6.4%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.9ms